About Adaptive Phage Therapeutics
Adaptive Phage Therapeutics is a company based in Bethesda (United States) founded in 2016 was acquired by BiomX in March 2024.. Adaptive Phage Therapeutics has raised $107.87 million across 11 funding rounds from investors including Amgen, Lilly and Bayer. The company has 78 employees as of December 31, 2022. Adaptive Phage Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
- Headquarter Bethesda, United States
- Employees 78 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adaptive Phage Therapeutics
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has successfully raised a total of $107.87M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series B — $12.0M
-
First Round
First Round
(13 Apr 2017)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Series B - Adaptive Phage Therapeutics | Valuation |
investors |
|
| Apr, 2022 | Amount | Series B - Adaptive Phage Therapeutics | Valuation | Lilly , Amgen | |
| Sep, 2021 | Amount | Grant - Adaptive Phage Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adaptive Phage Therapeutics
Adaptive Phage Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, Lilly and Bayer. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in antimicrobial resistance treatment development.
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Healthcare startups are accelerated by Mayo Clinic Business Accelerator.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adaptive Phage Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Adaptive Phage Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adaptive Phage Therapeutics Comparisons
Competitors of Adaptive Phage Therapeutics
Adaptive Phage Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Microbiome therapeutics are developed for dysbiosis-linked diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adaptive Phage Therapeutics
Frequently Asked Questions about Adaptive Phage Therapeutics
When was Adaptive Phage Therapeutics founded?
Adaptive Phage Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Adaptive Phage Therapeutics located?
Adaptive Phage Therapeutics is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
Is Adaptive Phage Therapeutics a funded company?
Adaptive Phage Therapeutics is a funded company, having raised a total of $107.87M across 11 funding rounds to date. The company's 1st funding round was a Grant of $8M, raised on Apr 13, 2017.
How many employees does Adaptive Phage Therapeutics have?
As of Dec 31, 2022, the latest employee count at Adaptive Phage Therapeutics is 78.
What does Adaptive Phage Therapeutics do?
Adaptive Phage Therapeutics was founded in 2016 and is based in Bethesda, United States. Operations focus on the biotechnology sector, where therapies for multi-drug resistant bacterial infections are provided through PhageBanking, a collection of targeted bacteriophages. A rapid matching system pairs phages with patient-specific infections. Success in a first-in-human case involving Acinetobacter baumannii has been achieved, supporting patient survival.
Who are the top competitors of Adaptive Phage Therapeutics?
Adaptive Phage Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are Adaptive Phage Therapeutics's investors?
Adaptive Phage Therapeutics has 12 investors. Key investors include Amgen, Lilly, Bayer, ARE, and Mayo Clinic.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.